– UK, London – SpectrumX, UK-based healthcare, and pharmaceutical company, today announced the appointment of Debra Leeves to its Board as Non-Executive Director, and also announced Barry Saint joining the company as CFO.
About Barry Saint
Barry Saint, who worked alongside the company before joining full time in January, brings over 25 years of experience in senior finance roles for public and private companies and in investment banking with Dresdner Kleinwort. Most recently, Barry was CFO of an early-stage biotechnology company, Camallergy. Before that, he served as Global Director of Corporate Finance and Group Treasurer of FTSE-250 specialty pharmaceuticals group, Indivior, which was formed through a $1.4 billion demerger from Reckitt Benckiser.
During his career, Barry has worked extensively in the healthcare, pharmaceutical, and biotechnology sectors. Returning recently from several years in the US, he has guided company boards and backers to source and secure international, value-accretive collaborations. He has substantial US, UK, and cross-border experience in M&A, debt and equity financing projects, and raising capital for growth companies, including at the IPO stage.
About Debra Leeves
Pharmaceutical industry expert Debra Leeves brings over 25 years of international experience in both business and clinical roles including sales, marketing, finance, quality, and medical affairs. Debra has held board roles amongst public and private companies including senior-level positions in both start-ups and large multinationals, such as Pfizer, GSK, and GE Healthcare.
Currently, Debra serves as CEO for Vertual Ltd, a leading global supplier of virtual reality training systems in radiation therapy, and was previously CEO of Physeon GmbH and Managing Director for Avita Medical Ltd. Additionally, she currently serves as Chair of Atelerix, Chair of the Institute of Directors (East Yorkshire) and Non-Executive Director of AIM-listed Cambridge Cognition.
Debra Leeves said: “SpectrumX is developing ground-breaking treatments for patients across the world and I am excited to be joining as the company pushes forward the market roll-out of its proprietary HOCI formulations. I look forward to working with the dedicated and skilled leadership team and supporting their long-term growth strategy as it disrupts and enhances the pharmaceutical industry.”
About SpectrumX
SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market a ground-breaking respiratory therapy (SPC-069) and the rollout of the most powerful hand sanitizer in the world to the NHS and other healthcare clients. Both products utilize unique patent-pending HOCl formulations. HOCl is naturally occurring in human white blood cells and is a key contributor to mankind’s evolution and protection over millions of years. It is human safe whilst also being the most effective disinfectant known to mankind.
For more information: https://spectrumx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.